• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Pilot Study of Racial Differences in the Current Definition of Sarcopenia among Liver Transplant Candidates.肝移植候选者中肌肉减少症当前定义的种族差异的初步研究。
Hawaii J Health Soc Welf. 2020 May 1;79(5):161-167.
2
A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort.一个包含肌肉减少症的模型在预测肝硬化肝移植候选者等待名单死亡率方面优于 MELD 评分:一项全国队列的竞争风险分析。
J Hepatol. 2018 Apr;68(4):707-714. doi: 10.1016/j.jhep.2017.11.030. Epub 2017 Dec 6.
3
Low skeletal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation-a retrospective study.低骨骼肌量与肝硬化患者肝移植名单上的住院费用增加相关——一项回顾性研究。
Transpl Int. 2018 Feb;31(2):165-174. doi: 10.1111/tri.13048. Epub 2017 Sep 21.
4
A multicenter study to define sarcopenia in patients with end-stage liver disease.一项界定终末期肝病患者肌少症的多中心研究。
Liver Transpl. 2017 May;23(5):625-633. doi: 10.1002/lt.24750.
5
Liver transplantation arrests and reverses muscle wasting.肝移植可阻止并逆转肌肉萎缩。
Clin Transplant. 2015 Mar;29(3):216-21. doi: 10.1111/ctr.12506. Epub 2015 Jan 27.
6
Use of Skeletal Muscle Index as a Predictor of Wait-List Mortality in Patients With End-Stage Liver Disease.骨骼肌指数用作终末期肝病患者等待移植死亡率的预测指标。
Liver Transpl. 2020 Sep;26(9):1090-1099. doi: 10.1002/lt.25802. Epub 2020 Aug 6.
7
Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list.肌少症 HIBA 评分可预测肝移植等待名单患者的肌少症和死亡率。
Hepatol Commun. 2022 Jul;6(7):1699-1710. doi: 10.1002/hep4.1919. Epub 2022 Mar 3.
8
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.肝移植等待名单患者的严重肌肉消耗:其流行程度和独立预后价值。
Liver Transpl. 2012 Oct;18(10):1209-16. doi: 10.1002/lt.23495.
9
Should Sarcopenia Increase Priority for Transplant or Is It a Contraindication?肌肉减少症应提高移植优先级还是它是一个禁忌症?
Curr Gastroenterol Rep. 2018 Sep 26;20(11):50. doi: 10.1007/s11894-018-0656-3.
10
Psoas Muscle Index Does Not Predict Post-Transplant Outcomes: A Series of 57 Liver Transplant Recipients.腰大肌指数不能预测肝移植术后结局:57例肝移植受者的系列研究
Transplant Proc. 2020 Mar;52(2):549-552. doi: 10.1016/j.transproceed.2019.12.032. Epub 2020 Feb 4.

引用本文的文献

1
Association of vitamins B1 and B2 intake with early-onset sarcopenia in the general adult population of the US: a cross-sectional study of NHANES data from 2011 to 2018.美国普通成年人群中维生素B1和B2摄入量与早发性肌肉减少症的关联:对2011年至2018年美国国家健康与营养检查调查(NHANES)数据的横断面研究
Front Nutr. 2024 Mar 8;11:1369331. doi: 10.3389/fnut.2024.1369331. eCollection 2024.
2
Variation in skeletal muscle mass among patients with cirrhosis of different self-identified race/ethnicity.不同自我认定种族/族裔的肝硬化患者骨骼肌质量的差异。
JGH Open. 2023 Sep 20;7(10):724-727. doi: 10.1002/jgh3.12976. eCollection 2023 Oct.
3
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease.非酒精性脂肪性肝病/代谢相关脂肪性肝病中的肌少症骨量减少症:慢性肝病中一个被低估的临床问题。
Int J Mol Sci. 2023 Apr 19;24(8):7517. doi: 10.3390/ijms24087517.
4
Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions.肝硬化患者的肌肉减少症:当前认知与未来方向
J Clin Exp Hepatol. 2023 Jan-Feb;13(1):162-177. doi: 10.1016/j.jceh.2022.06.005. Epub 2022 Jun 27.

本文引用的文献

1
Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration.肝性脑病与肌肉减少症:同一代谢改变的两面
J Clin Exp Hepatol. 2019 Jan-Feb;9(1):125-130. doi: 10.1016/j.jceh.2018.04.007. Epub 2018 May 5.
2
CT-quantified muscle and fat change in patients after surgery or endoscopic resection for early gastric cancer and its impact on long-term outcomes.早期胃癌手术或内镜切除术后患者的CT定量肌肉和脂肪变化及其对长期预后的影响。
Medicine (Baltimore). 2018 Dec;97(52):e13878. doi: 10.1097/MD.0000000000013878.
3
Prevalence and Associated Factors of Sarcopenia in Nursing Home Residents: A Systematic Review and Meta-analysis.养老院居民肌少症的患病率及相关因素:系统评价和荟萃分析。
J Am Med Dir Assoc. 2019 Jan;20(1):5-13. doi: 10.1016/j.jamda.2018.09.012. Epub 2018 Nov 5.
4
Sarcopenia is a Predictive Factor for Postoperative Morbidity and Mortality in Patients Having Radical Gastrectomy for Cancer.肌肉减少症是癌症根治性胃切除患者术后发病和死亡的预测因素。
Chirurgia (Bucur). 2018 Sept-Oct;113(5):678-686. doi: 10.21614/chirurgia.113.5.678.
5
Association Between Sarcopenic Obesity and Falls in a Multiethnic Cohort of Postmenopausal Women.肌少症性肥胖与绝经后多民族队列妇女跌倒的关系。
J Am Geriatr Soc. 2018 Dec;66(12):2314-2320. doi: 10.1111/jgs.15613. Epub 2018 Oct 30.
6
Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis.肌肉减少症与肝硬化肝性脑病有关吗?系统评价和荟萃分析。
J Formos Med Assoc. 2019 Apr;118(4):833-842. doi: 10.1016/j.jfma.2018.09.011. Epub 2018 Sep 29.
7
Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis.在肝硬化患者中,腰大肌指数对预测等待名单死亡率高的患者的表现不佳。
J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1053-1062. doi: 10.1002/jcsm.12349. Epub 2018 Sep 29.
8
Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis.肌肉减少症和肌少症性肥胖与胰腺癌患者总体生存率降低显著相关:系统评价和荟萃分析。
Int J Surg. 2018 Nov;59:19-26. doi: 10.1016/j.ijsu.2018.09.014. Epub 2018 Sep 25.
9
Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease.肌肉减少症和衰弱症对非酒精性脂肪性肝炎和酒精性肝病的影响不同。
Liver Transpl. 2019 Jan;25(1):14-24. doi: 10.1002/lt.25346.
10
Pretransplant Sarcopenia in Patients With NASH Cirrhosis Does Not Impact Rehospitalization or Mortality.NASH 肝硬化患者移植前肌少症不会影响再住院或死亡率。
J Clin Gastroenterol. 2019 Oct;53(9):680-685. doi: 10.1097/MCG.0000000000001109.

肝移植候选者中肌肉减少症当前定义的种族差异的初步研究。

A Pilot Study of Racial Differences in the Current Definition of Sarcopenia among Liver Transplant Candidates.

作者信息

Sempokuya Tomoki, Yokoyama-Arakaki Leigh, Wong Linda L, Kalathil Sumodh

机构信息

Transplant Center, The Queen's Medical Center, Honolulu, HI (LY-A, LLW).

出版信息

Hawaii J Health Soc Welf. 2020 May 1;79(5):161-167.

PMID:32432222
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7226313/
Abstract

Sarcopenia has been shown to have prognostic value in patients awaiting liver transplant. However, the presence of sarcopenia as a prognostic factor among patients awaiting liver transplantation might vary by race. This study aims to assess racial differences of sarcopenia in liver transplant candidates. This retrospective study assessed 102 patients on a liver transplantation list from 2012 to 2016 and used demographic and clinical variables to predict sarcopenia as measured by skeletal muscle index (SMI) and death or removal from the transplant list. Three racial groups were compared in the study: whites (n=34), Asians (n=50), and Native Hawaiians and Other Pacific Islanders (NHOPIs; n=18). NHOPI were more likely to have a body mass index (BMI) ≥ 30 and hepatitis B, and less likely to have alcoholic cirrhosis and sarcopenia than whites. Asians were more likely to have hepatitis B and less likely to have alcoholic cirrhosis and encephalopathy than other races. Using logistic regression, a BMI ≥ 30, multiple waiting list events, alcoholic cirrhosis, and sarcopenia were predictive of death or removal from the list. Although NHOPI had a higher BMI, they had less sarcopenia and similar frequency of ascites, encephalopathy, multiple waiting list events, and death or removal from the list compared to other races. Racial variations in muscle mass might have resulted in fewer NHOPI having sarcopenia as defined by the US criteria. Larger studies of patients with varying ethnicity are needed to develop a universally applicable definition of sarcopenia before we use this for liver transplant listing or allocation.

摘要

肌肉减少症已被证明在等待肝移植的患者中具有预后价值。然而,肌肉减少症作为肝移植等待患者预后因素的存在可能因种族而异。本研究旨在评估肝移植候选者中肌肉减少症的种族差异。这项回顾性研究评估了2012年至2016年在肝移植名单上的102名患者,并使用人口统计学和临床变量来预测通过骨骼肌指数(SMI)测量的肌肉减少症以及死亡或从移植名单上移除的情况。研究中比较了三个种族群体:白人(n = 34)、亚洲人(n = 50)以及夏威夷原住民和其他太平洋岛民(NHOPIs;n = 18)。与白人相比,NHOPIs更有可能体重指数(BMI)≥ 30且患有乙型肝炎,而患酒精性肝硬化和肌肉减少症的可能性较小。与其他种族相比,亚洲人更有可能患有乙型肝炎,而患酒精性肝硬化和肝性脑病的可能性较小。使用逻辑回归分析,BMI≥ 30、多次等待名单事件、酒精性肝硬化和肌肉减少症可预测死亡或从名单上移除。尽管NHOPIs的BMI较高,但与其他种族相比,他们的肌肉减少症较少,腹水、肝性脑病、多次等待名单事件以及死亡或从名单上移除的频率相似。肌肉量的种族差异可能导致按照美国标准定义的肌肉减少症的NHOPIs较少。在将肌肉减少症用于肝移植名单登记或分配之前,需要对不同种族的患者进行更大规模的研究,以制定一个普遍适用的肌肉减少症定义。